封面
市場調查報告書
商品編碼
1198698

尿失禁設備市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Urinary Incontinence Treatment Devices Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 122 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計 2021 年尿失禁治療設備市場價值 33.9292 億美元,預測期內復合年增長率為 6.6%。

多個國家在 2020 年 COVID-19 大流行初期進入封鎖狀態。由於與其他國家的貿易暫停和旅行限制,2020 年上半年診斷和手術有所下降。

根據British Journal of Surgery 2020 年 5 月發表的一項研究,假設因 COVID-19 大流行導致醫院服務中斷 12 週的高峰期,2020 年全球將有大約 2840 萬例擇期手術被取消或推遲。此外,根據國際財團 2020 年 5 月進行的一項研究,由於 COVID-19 流行病,印度有超過 580,000 例擇期手術被取消或推遲。

促進市場增長的一個主要因素是尿失禁 (UI) 患病率的上升。許多因素會導致尿失禁的發生,包括尿路感染、盆底肌和尿道括約肌減弱、更年期、懷孕、分娩和男性根治性前列腺切除術後。在 2021 年 6 月發表的題為 "Prevalence of Urinary Incontinence among Young Healthy Females in Gujarat-A Cross-sectional Study" 的研究中,經過 2017 年 12 月至 2018 年 10 月為期 11 個月的調查期後,尿失禁在年齡較大的健康年輕女性中的患病率18-25歲人群佔71.85%,其中壓力型尿失禁佔50.85%,急迫型占9.16%,混合型占40%。

美國國家生物技術信息中心(NCBI)發表的一篇題為《絕經後婦女尿失禁(2019)》的論文發現,帕金森病、糖尿病、多發性硬化症等多種疾病的發病率都在增加,而且無論男女兩者都被認為會增加尿失禁的患病率。因此,預計在預測期內對尿失禁治療設備的需求將會增加。此外,對微創手術的需求不斷增長和技術不斷進步也有望推動市場增長。增加 UI 領域的研發正在提高公眾意識並探索市場機會,這有望推動市場增長。

此外,市場參與者正在採取各種策略,如產品發布、開發、收購、合併和合作夥伴關係,以擴大其在所研究市場中的產品組合,這正在推動市場的增長。例如,2019年11月,Renovia Inc.宣布了下一代leva Pelvic Digital Therapeutic,用於增強盆底肌肉,治療女性壓力性/混合性尿失禁和輕度至中度緊急尿失禁(UI)。宣布獲得美國食品和藥物管理局 (FDA) 的 510(k) 批准。

然而,諸如缺乏對疾病設備和社會恥辱的認識以及與程序相關的風險和並發症等因素預計將阻礙預測期內的市場增長。

尿失禁治療設備的市場趨勢

預計尿道吊帶部分將在預測期內實現健康增長

由於尿道吊帶被強烈推薦作為治療壓力性尿失禁的手術方法,因此尿道吊帶部分有望出現增長。

2020 年 8 月發表的一項題為 "A Global Survey on the Impact of COVID-19 on Urological Services" 的研究發現,尿失禁、良性前列腺增生、不孕不育和性門診的內科、腎結石、陰囊良性疾病和膀胱結石受影響最大。此外,2020年疫情期間,各類門診檢查和手續全線下降。特別是,針對女性尿失禁、不孕症、腎結石和膀胱結石的外科手術服務減少最多。這些對該部門的增長產生了負面影響。

尿道吊帶手術也稱為尿道中部吊帶手術。所用的吊帶材料可以是取自雌性、豬等動物的肌肉、韌帶和肌腱組織。它們也可以由合成材料製成,例如與身體組織相容的塑料或隨時間分解的可吸收聚合物。

根據 2021 年 2 月發表的文章《女性尿失禁很常見但可以治療》,尿失禁是不受控制的尿液漏出,從幾滴到完全意外不等。50 歲以上的女性中,近二分之一正在處理問題與尿失禁有關。文章還指出,超過 2500 萬美國人經常承認有膀胱控制問題。女性尿失禁率上升和人口老齡化增加了對尿道吊帶手術的需求。

此外,由於手術後恢復快,患者對它的需求量很大。除了吊帶手術帶來的低風險和益處外,對微創手術不斷增長的需求也推動了這一領域的增長。

波士頓科學公司於 2019 年 2 月重新設計並推出了 Mesh Sling System,這是一種用於男性患者壓力性尿失禁的外科植入物。這種手術網也被植入以支撐尿道頸,以糾正壓力性尿失禁 (SUI)。

此外,尿失禁量的增加和尿失禁治療研究的積累是尿道吊帶領域增長的主要因素。

預計在預測期內,北美將佔據重要的市場份額

推動北美地區市場增長的主要因素包括尿失禁 (UI) 患病率的增加、老年人口的增加以及該地區對微創手術的需求。

由於 COVID-19 大流行,泌尿外科平台市場參與者的收入下降。例如,康樂保公司的介入泌尿科部門在 2019-20 財年實現了負有機增長(-7%)。這種負增長主要是由於 Altis 單切口吊帶等產品的銷量下降,其次是 COVID-19 爆發後美國取消了選擇性手術和程序。由於 COVID-19 流行病,美國以外的國家也推遲了擇期手術。

儘管受到其他因素的大流行的負面影響,但研究的市場顯示北美地區的增長。根據加拿大政府統計報告,截至2019年7月,加拿大老年人口為6,592,611人,佔加拿大總人口的17.5%。隨著時間的推移,加拿大老年人口的比例一直在增加。人口老齡化的出現對加拿大尿失禁設備市場產生了積極影響,因為膀胱控制問題、尿漏和尿失禁等膀胱疾病的風險隨著年齡的增長而增加。

根據 2021 年 6 月發表在 Medscape 上的一篇文章“尿失禁的患病率是多少?”,估計 UI 在美國影響了 10-13 百萬人。此外,僅在美國,治療 UI 的費用就達 163 億美元,其中 75% 花在了女性身上。因此,UI 在美國的流行率正在上升,預計這將推動市場的增長。

主要參與者為加強市場地位而採取的研發、併購和產品發布等戰略也是推動所研究市場增長的因素。2020 年 2 月,Atlantic Therapeutics 獲得美國食品和藥物管理局(FDA)批准 INNOVO,這是一種經臨床驗證的非侵入性可穿戴設備,用於治療成年女性壓力性尿失禁(SUI)。宣布已授予超過-櫃檯銷售許可。因此,預計這些因素將在預測期內推動該地區的尿失禁治療設備市場。

尿失禁設備市場的競爭對手分析

尿失禁治療設備市場競爭激烈。目前主導市場的公司包括 Boston Scientific Corporation、Becton、Dickinson and Company、Coloplast Corp.、Promedon Group、AMI GmbH、Johnson & Johnson、Zephyr Surgical Implants、Medtronic PLC、Caldera Medical Inc.、Hollister Incorporated、Nipro Corporation、Karl Storz SE & Co.KG、B Braun Melsungen AG、Baxter International Inc.、ConvaTec Group PLC 等。

其他福利

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

目錄

第 1 章 簡介

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第三章執行摘要

第四章市場動態

  • 市場概況
  • 市場驅動力
    • 尿失禁患病率上升和人口老齡化
    • 對微創手術和產品開發的需求不斷增長
  • 市場製約因素
    • 關於尿失禁的低意識和社會恥辱感
    • 手術風險和並發症
  • 波特五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭對手之間的競爭

第 5 章市場細分(基於價值的市場規模:百萬美元)

  • 按產品
    • 尿道吊帶
    • 電刺激器
    • 人工尿道括約肌
    • 導尿管,其他
  • 按最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 歐洲其他地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 亞太其他地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 中東其他地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美地區

第六章公司概況及競爭格局

  • 公司簡介
    • Boston Scientific Corporation
    • BD
    • Colopast Group
    • PROMEDON GmbH
    • AMI GmbH
    • Johnson & Johnson(Ethicon)
    • Zephyr Surgical Implants
    • Medtronic
    • Caldera Medical Inc.
    • Hollister Incorporated
    • KARL STORZ SE & Co. KG
    • B Braun Melsungen AG
    • ConvaTec Group PLC

第七章市場機會與未來趨勢

簡介目錄
Product Code: 68593

The urinary incontinence treatment devices market was valued at USD 3392.92 million in 2021 and is expected to record a CAGR of 6.6% during the forecast period.

In the initial days of the COVID-19 pandemic in 2020, several countries were in lockdown. Suspension in trade with other countries and travel restrictions led to a decline in diagnosis and surgical procedures in the first half of 2020.

According to a study published in the British Journal of Surgery, in May 2020, based on a 12-week period of peak disruption for hospital services due to the COVID-19 pandemic, around 28.4 million elective surgeries worldwide were canceled or postponed in 2020. In addition, more than 580,000 planned surgeries in India were canceled or delayed because of the COVID-19 pandemic, according to a study conducted by an international consortium in May 2020.

The major factor contributing to the market's growth is the rising prevalence of urinary incontinence (UI). Numerous factors such as urinary tract infection, weakening of pelvic floor muscles and urethral sphincters, menopause, pregnancy, childbirth, and post-radical prostatectomy surgery in men lead to the development of urinary incontinence symptoms. A study titled "Prevalence of Urinary Incontinence among Young Healthy Females in Gujarat - A Cross-sectional Study," published in June 2021, found that after the study period of 11 months from December 2017 to October 2018, among the total population, the prevalence of UI was 71.85% among young women who were healthy and aged between 18-25 years, of whom 50.85% had stress, 9.16% had urge, and 40% had a mixed type of urinary incontinence.

An article titled "Urinary Incontinence in Postmenopausal Women (2019)," published in the National Center for Biotechnology Information (NCBI), found that there has been a rise in the incidence of various diseases, such as Parkinson's disease, diabetes, multiple sclerosis, etc., which may lead to increased prevalence of urinary incontinence in males and females. This is expected to boost demand for urinary incontinence treatment devices over the forecast period. Furthermore, the growing demand for minimally invasive procedures and increasing technological advancements are expected to boost market growth. Increasing research and development in the field of UI is creating awareness among people and opportunities in the market studied, which is expected to propel the market's growth.

Moreover, market players are adopting various strategies, such as product launches, developments, acquisitions, mergers, and collaborations, to expand their product portfolio in the market studied, which is boosting the market growth. For instance, in November 2019, Renovia Inc. announced the US Food and Drug Administration's (FDA) 510(k) clearance for its next-generation leva Pelvic Digital Therapeutic, which will be used for strengthening pelvic floor muscles and for the treatment of stress and mixed and mild to moderate urgency urinary incontinence (UI) in women.

However, factors such as a lack of awareness about devices and social stigma associated with the disease, and the risks and complications related to the procedures, are expected to impede market growth over the forecast period.

Urinary Incontinence Treatment Devices Market Trends

Urethral Slings Segment Expected to Witness Healthy Growth over the Forecast Period

The urethral slings segment is expected to witness growth as these are highly recommended for surgical treatment for the treatment of stress urinary incontinence.

A study entitled "A Global Survey on the Impact of COVID-19 on Urological Services," published in August 2020, showed that during the COVID-19 pandemic, the outpatient clinics for female urinary incontinence, benign prostatic hyperplasia, infertility, sexual medicine, renal stone, benign scrotal conditions, and bladder stone were the most affected, among others. Besides, there was a decline across various types of outpatient investigations and procedures during the outbreak in 2020. Particularly surgical procedures for female urinary incontinence, infertility, renal stones, and bladder stones had the highest rates of decline in services. These affected the growth of the segment negatively.

Urethral slings surgery is also known as mid-urethral sling surgery. The sling material used may be muscle, ligament, or tendon tissue taken from the woman or an animal, such as a pig. It may also be composed of synthetic material, such as plastic compatible with body tissues or absorbable polymer that disintegrates over time.

According to an article published in February 2021, titled "Urinary Incontinence in Women Common, but Treatable," urinary incontinence is the unconditional loss of urine, which can be a few drops of leakage to a full accident and almost 1 in 2 women over the age of 50 years deal with issues related to urinary incontinence. This article also mentioned that more than 25 million Americans admit that they regularly face issues controlling their bladders. The rising prevalence of urinary incontinence among women and the aging population is boosting the demand for urethral sling surgery.

Furthermore, the quick recovery time of procedures is increasing its demand among the patient population. Apart from the low risk rates and advantages offered by sling procedures, the increasing demand for minimally invasive surgeries is also boosting the segment's growth.

Boston Scientific launched a redesign of its mesh sling system in February 2019, which is a surgical implant for stress urinary incontinence in male patients. The surgical mesh is also implanted to support the urethra neck to correct stress urinary incontinence (SUI).

Moreover, the growing volume of urinary incontinence and cumulative research in urinary incontinence treatment are the major factors for the growth of the urethral slings segment.

North America Expected to Hold a Significant Market Share over the Forecast Period

The major factors driving the market growth in the North American region are increases in the prevalence of urinary incontinence (UI), the geriatric population, and the demand for minimally invasive surgeries in the region.

Urology platform market players suffered a decline in revenues due to the COVID-19 pandemic. For instance, the interventional urology segment of Coloplast Corp. generated negative organic growth (-7%) in the financial year 2019-20. The negative growth was mainly due to a decrease in sales of Altis single-incision slings and other products, followed by the cancellation of elective surgeries and procedures in the US after the COVID-19 outbreak. Elective procedures outside the US were also postponed in several countries during the COVID-19 outbreak.

The market studied has shown growth in the North American region despite the negative impact of the pandemic owing to other factors. As of July 2019, the Canadian geriatric population included 6,592,611 people, which accounted for 17.5% of the Canadian population, as per the Government of Canada's statistics report. The proportion of senior citizens in Canada has been increasing with time. As aging increases the risk of bladder problems such as bladder control issues, and leakage or urinary incontinence, thus, the increasing aging population is positively influencing the Canadian urinary incontinence treatment devices market.

As per the article published in Medscape in June 2021, titled, "What is the prevalence of urinary incontinence?," it was estimated that UI would affect 10-13 million people in the US. Additionally, the cost of treatment of UI in the US alone is USD 16.3 billion, 75% of which is spent on the treatment of women. This increasing prevalence of UI in the US is expected to propel the market's growth.

Strategies adopted by major companies, such as research and development, mergers and acquisitions, and product launches to strengthen their market position are another driving factor for the growth of the market studied. In February 2020, Atlantic Therapeutics announced that the US Food and Drug Administration (FDA) had granted over-the-counter (OTC) clearance to INNOVO, a non-invasive, clinically proven, and wearable device for the treatment of stress urinary incontinence (SUI) in adult females. Therefore, these aforementioned factors are expected to boost the urinary incontinence treatment devices market in the region over the forecast period.

Urinary Incontinence Treatment Devices Market Competitor Analysis

The urinary incontinence treatment devices market is moderately competitive. Some of the companies currently dominating the market are Boston Scientific Corporation, Becton, Dickinson and Company, Coloplast Corp., Promedon Group, AMI GmbH, Johnson & Johnson, Zephyr Surgical Implants, Medtronic PLC, Caldera Medical Inc., Hollister Incorporated, Nipro Corporation, Karl Storz SE & Co. KG, B Braun Melsungen AG, Baxter International Inc., and ConvaTec Group PLC, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Urinary Incontinence and Rise in Geriatric Population
    • 4.2.2 Rise in Demand for Minimally Invasive Surgery and Product Development
  • 4.3 Market Restraints
    • 4.3.1 Lack of Awareness about Devices and Social Stigma Associated with the Disease
    • 4.3.2 Risks and Complications from the Procedures
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Urethral Slings
    • 5.1.2 Electrical Stimulation Devices
    • 5.1.3 Artificial Urinary Sphincters
    • 5.1.4 Catheters and Others
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPANY PROFILES AND COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 BD
    • 6.1.3 Colopast Group
    • 6.1.4 PROMEDON GmbH
    • 6.1.5 AMI GmbH
    • 6.1.6 Johnson & Johnson (Ethicon)
    • 6.1.7 Zephyr Surgical Implants
    • 6.1.8 Medtronic
    • 6.1.9 Caldera Medical Inc.
    • 6.1.10 Hollister Incorporated
    • 6.1.11 KARL STORZ SE & Co. KG
    • 6.1.12 B Braun Melsungen AG
    • 6.1.13 ConvaTec Group PLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS